<?xml version="1.0" encoding="UTF-8"?><CodeSystem xmlns="http://hl7.org/fhir">
  <id value="research-study-phase"/>
  <meta>
    <lastUpdated value="2020-12-28T16:55:11.085+11:00"/>
    <profile value="http://hl7.org/fhir/StructureDefinition/shareablecodesystem"/>
  </meta>
  <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-wg">
    <valueCode value="brr"/>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status">
    <valueCode value="draft"/>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm">
    <valueInteger value="1"/>
  </extension>
  <url value="http://terminology.hl7.org/CodeSystem/research-study-phase"/>
  <identifier>
    <system value="urn:ietf:rfc:3986"/>
    <value value="urn:oid:2.16.840.1.113883.4.642.4.1247"/>
  </identifier>
  <version value="5.0.0"/>
  <name value="ResearchStudyPhase"/>
  <title value="ResearchStudyPhase"/>
  <status value="draft"/>
  <experimental value="false"/>
  <date value="2020-12-28T16:55:11+11:00"/>
  <publisher value="HL7 (FHIR Project)"/>
  <contact>
    <telecom>
      <system value="url"/>
      <value value="http://hl7.org/fhir"/>
    </telecom>
    <telecom>
      <system value="email"/>
      <value value="fhir@lists.hl7.org"/>
    </telecom>
  </contact>
  <description value="Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation."/>
  <caseSensitive value="true"/>
  <valueSet value="http://hl7.org/fhir/ValueSet/research-study-phase"/>
  <content value="complete"/>
  <concept>
    <code value="n-a"/>
    <display value="N/A"/>
    <definition value="Trials without phases (for example, studies of devices or behavioral interventions)."/>
  </concept>
  <concept>
    <code value="early-phase-1"/>
    <display value="Early Phase 1"/>
    <definition value="Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0."/>
  </concept>
  <concept>
    <code value="phase-1"/>
    <display value="Phase 1"/>
    <definition value="Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients."/>
  </concept>
  <concept>
    <code value="phase-1-phase-2"/>
    <display value="Phase 1/Phase 2"/>
    <definition value="Trials that are a combination of phases 1 and 2."/>
  </concept>
  <concept>
    <code value="phase-2"/>
    <display value="Phase 2"/>
    <definition value="Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks."/>
  </concept>
  <concept>
    <code value="phase-2-phase-3"/>
    <display value="Phase 2/Phase 3"/>
    <definition value="Trials that are a combination of phases 2 and 3."/>
  </concept>
  <concept>
    <code value="phase-3"/>
    <display value="Phase 3"/>
    <definition value="Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug."/>
  </concept>
  <concept>
    <code value="phase-4"/>
    <display value="Phase 4"/>
    <definition value="Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use."/>
  </concept>
</CodeSystem>